SRZN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Surrozen Inc (SRZN) is not a strong buy at the moment for a beginner, long-term investor. While there are some positive catalysts such as insider buying and bullish moving averages, the company's financial performance is weak with declining revenue and negative gross margins. Additionally, there are no strong trading signals or recent news catalysts to support an immediate buy decision.
The technical indicators show mixed signals. The MACD is positive and contracting, RSI is neutral at 54.199, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot level of 26.917, with resistance at 29.347 and support at 24.488.
Insiders are buying significantly, with a 661.32% increase in insider buying over the last month. Analysts have raised price targets, with H.C. Wainwright setting a target of $36 and Cantor Fitzgerald initiating coverage with a $40 target.
The company's financial performance is weak, with a 19.39% YoY revenue decline, 100% drop in gross margin, and a significant net income loss despite some YoY improvement. No recent news or congress trading data is available to act as a catalyst.
In Q4 2025, revenue dropped 19.39% YoY to $528,000. Net income improved to -$183.16M (up 553.23% YoY), but gross margin fell to 0 (-100% YoY). EPS improved to -32.37, up 275.52% YoY. Overall, financials show weak growth trends.
Analysts are optimistic, with H.C. Wainwright raising the price target to $36 and Cantor Fitzgerald initiating coverage with an Overweight rating and a $40 target. Both analysts highlight the company's leadership in Wnt biology and its potential in treating retinal diseases.
